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The study aims to identify other collagen genes that may significantly 
define subconjunctival fibrosis following experimental glaucoma 
filtration surgery.
Methods: Subconjunctival scarring was induced using a mouse 
model of glaucoma filtration surgery (GFS). The early and late 
phases of wound healing were analyzed by RNA sequencing 
(RNA-seq). The top ten highest expressed collagen genes in the 
late phase were validated by quantitative polymerase chain reaction 
(qPCR). Immunoblotting and immunolocalization were performed 
to verify and determine the expression profiles of the top three 
highest expressed collagen genes. Mouse and human conjunctival 
fibroblasts were treated with TGF-β2 to determine the inducibility of 
the collagen transcripts. Conjunctival tissues, collected from 20 and 
15 patients requiring initial and repeat GFS respectively were also 
analyzed by qPCR.
Results: RNA-seq identified Col8a1 (70-fold), Col11a1 (40-fold) 
and Col8a2 (20-fold) as the three most highy expressed collagen 
genes in the late phase conjunctival transcriptome. These collagens 
were also induced at the protein level in late phase tissues. Type VIII 
collagen co-localized with type I collagen in fibrous structures and 
in ACTA-2-positive pericytes, appearing to fill gaps where type I 
collagen was low. Type XI collagen showed little co-localization with 
both collagens but was associated with the presence of macrophages. 
TGF-β2 induced the top ten collagen genes in both mouse and human 
conjunctival fibroblasts. Conjunctival tissues from eyes undergoing 
repeat trabeculectomy surgery expressed 3.60-fold and 2.78-fold 
increase in type VIII and I collagen transcripts respectively compared 
to conjunctival tissues from primary trabeculectomy.
Conclusions: The high induction and unique expression profiles of 
types VIII and XI collagen suggest that together with collagen I, form 
a group of collagen biomarkers for the evaluation of fibrosis in the 
mouse model of GFS and post trabeculectomies.
Commercial Relationships: Tina T. Wong, None; Li Zhen Toh, 
None; Stephanie Chu, None; Jocelyn Chua, None; Li Fong Seet, 
None
Support: NMRC/TCR/008/2013
Program Number: 2926 Poster Board Number: A0275
Presentation Time: 8:30 AM–10:15 AM
Utility of purified collagenase (Xiaflex®) as a possible aid in 
glaucoma surgery: A pilot study
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Purpose: Trabeculectomy ab externo (Trab) remains one of the 
most commonly performed surgeries targeted at lowering intraocular 
pressure (IOP). Post-operative episcleral fibrosis over the scleral 
flap is a common cause of failure. Modulation of wound healing 
with mitomycin C remains the current gold standard for inhibiting 
post-operative scarring, and has been shown to extend bleb survival 
to 30 days post-operatively in rabbits. We hypothesize that the use 
of a purified collagenase Xiaflex® (Endo Pharmaceutical, {Dublin, 
Ireland}) given perioperatively may extend the life of glaucoma 
filtering surgery and re-establish filtration post-operatively in a rabbit 
model of glaucoma filtering surgery.
Methods: 13 eyes of New Zealand White rabbits underwent limbal-
based Trab without the use of antifibrotic agents by the same surgeon 
(RH). Purified collagenase was delivered peri-operatively and 
post-operatively by subconjunctival injections of 12.5 µl volumes at 
varying concentrations. Post-operative filtration was assessed using 
Moorfield grading of the bleb on examination and photographs, IOP 
measurements via TonoPen®, fluorescein transmission through the 
bleb, and ultrasound biomicroscopy (UBM). Clinical bleb failure 
was defined as increase in IOP to baseline or failure of fluorescein 
transmission. Eyes undergoing surgery without the administration of 
collagenase were used as controls.
Results: Four eyes underwent both peri-operative and post-operative 
injections of Xiaflex, with improved survival time by IOP and 
fluorescein transmission compared to controls. Three of the four eyes 
demonstrated clinical bleb survival beyond 30 days post-operatively. 
Two of five eyes that underwent only post-operative injections 
demonstrated an improved survival time compared to controls. 
Four eyes in the control group demonstrated clinical bleb failure 
between 11 and 14 days. Adverse events included subconjunctival 
hemorrhage, eyelid ecchymosis, corneal ectasia and pannus, and 
conjunctival breakdown. Moorfield grading and UBM was found to 
be of limited value.
Conclusions: This pilot study preliminarily demonstrates that Xiaflex 
can extend the life of glaucoma filtering surgeries. Best results 
were obtained with peri-operative and post-operative injections of 
the medication. Further work must be done to optimize dosage and 
develop a delivery protocol prior to a formal efficacy study.
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Purpose: Post-surgical scarring remains the main cause of failure of 
glaucoma filtration surgery and current antimetabolites carry the risk 
of potentially blinding complications. There is increasing evidence 
that the Myocardin-related transcription factor/Serum response 
factor (MRTF/SRF) pathway plays a pivotal role in myofibroblast 
activation. We thus hypothesised that inhibiting the MRTF/SRF 
pathway would reduce scarring in an aggressive rabbit model of 
conjunctival fibrosis.
Methods: Ex vivo segments of rabbit conjunctiva were cultured in 
100μM MRTF inhibitor 1 or PBS control and imaged for tissue area 
changes over 30 days. We validated our results using a randomised, 
prospective, masked-observer study of 24 New Zealand White female 
rabbits undergoing glaucoma filtration surgery. The animals received 
either intraoperative 0.2mg/ml mitomycin-C (MMC) [N=6] or 
postoperative subconjunctival injections of 100μM MRTF inhibitor 
1 [N=6] or 100μM MRTF inhibitor 2 [N=6] or PBS [N=6]. Bleb 
morphology and intraocular pressure were recorded over 30 days. 
Tissue sections were immunohistochemically graded on day 30. We 
analysed our results using Kaplan-Meier curve Log-rank test and 
Student’s t-test.
Results: Ex vivo conjunctival tissue contraction was significantly 
reduced by 35%(day 6), 39%(day 15), 48%(day 21) and 68%(day 
30) with inhibitor 1 compared to PBS (Fig 1). In vivo, bleb survival 
was significantly improved with inhibitor 1 (p=0.01) and inhibitor 
2 (p=0.0005) compared to PBS (Fig 2). The mean day of bleb 
failure was 28.8 (range=24-30) for MMC, 28.5 (range=24-30) for 
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inhibitor 2, 24.5 (range=15-30) for inhibitor 1, and 14 (range=12-18) 
for PBS. IOP also remained significantly lower with inhibitor 1 
(p=0.027) and inhibitor 2 (p=0.0005) compared to PBS. MMC 
treatment led to thin avascular blebs with destruction of the epithelial 
layer. MRTF inhibitors however were not toxic and significantly 
reduced conjunctival scarring using H&E, picrosirius red, Gomori’s 
trichrome, and alpha-smooth muscle actin staining (p<0.05).
Conclusions: Novel MRTF inhibitors significantly improved bleb 
survival and prevented conjunctival scarring. MRTF inhibitor 2 had 
more potent anti-scarring effects than inhibitor 1. They were safe 
for subconjunctival delivery and less destructive to local tissue than 
MMC. MRTF inhibitors show potential as a novel class of anti-
fibrotic agents in glaucoma filtration surgery.
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Effects of rho-associated protein kinase inhibitor Y-27632 on 
scarring formation after glaucoma filtration surgery
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Purpose: Glaucoma filtration surgery usually fails because of post 
surgical scarring, a process in which fibroblasts play a prominent 
role. To elucidate the effects of rho-associated protein kinase (ROCK) 
inhibitor Y-27632 in post surgical scarring (fibrosis), we have now 
investigated the molecular mechanism with human tenon fibroblasts.
Methods: Human tenon fibroblasts were cultured with Y-27632 or 
various antiglaucoma drugs for indicated periods. After cultivation, 
we have prepared total RNA and protein samples from tenon 
fibroblasts. Using multiple RT-PCR array, we examined the factors 
respond to Y-27632. And, we have studied the expression of factor(s) 
of relating scarring formation using RT-PCR, immunoblot and 
immunofluorescence analysis. Also, we have examined the three-
dimensional collagen gels cultivation for gel contraction by various 
antiglaucoma drugs.
Results: Collagen gel contraction by tenon fibroblasts was blocked 
in the presence of Y-27632. In multiple RT-PCR array using fibrosis-
related genes, the expression of MMP-3 was down-regulated in tenon 
fibroblasts by additional Y-27632. Furthermore, immunoblot and 
immunoflurorescence analysis revealed that the expression of fibrosis 
markers was down-regulated in the presence of Y-27632.
Conclusions: These results suggest that the ROCK inhibitor 
Y-27632 may block scarring formation with interaction MMP-3 after 
glaucoma surgery. And, it will be possible that ROCK inhibitors 
and MMP-3 may have potential to be developed for treatment of 
glaucoma and other ocular diseases.
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Effects of ripasudil (K-115), a Rho kinase inhibitor, on the 
activation of human conjunctival fibroblasts
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Purpose: Ripasudil, a selective Rho kinase inhibitor, is an 
ophthalmic solution which was approved in Japan for the twice-daily 
treatment of glaucoma and ocular hypertension in 2014. The purpose 
of this study is to assess the effects of ripasudil on the activation of 
human conjunctival fibroblasts.
Methods: Human conjunctival fibroblasts were pretreated with or 
without different concentrations of ripasudil (25 and 50 μM) for 
1 hour and subsequently stimulated with 5 ng/ml TGF-β2 for 48 
hours. The effects of ripasudil on α-smooth muscle actin (α-SMA) 
expression and extracellular matrix (ECM) expression were analyzed 
by Western blot analysis. Contractile activity was evaluated by 
collagen gel contraction assay. Cell viability and cytotoxicity were 
assessed using WST-8 assay and Hoechst 33342/propidium iodide 
(PI) dual staining, respectively. The human monocytic cell line 
THP-1 were differentiated into M1- and M2-like macrophages, and 
fibroblasts were treated with conditioned medium derived from these 
macrophages in the presence or in the absence of 50 μM ripasudil to 
quantify the α-SMA expression level.
